Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M)Simona Di Giambenedetto, Antonella Castagna, Giancarlo Orofino et al.|Journal of Antimicrobial Chemotherapy|2016Cited by 75
Neuropsychiatric adverse events in people with HIV initiating a new integrase strand transfer inhibitor-based regimen in Italy: findings from the NEURO-INSTI studyNicola Squillace, Paolo Bonfanti, Elena Ricci et al.|BMC Infectious Diseases|2025Cited by 4
Effectiveness of first-line lamivudine/dolutegravir antiretroviral therapy in persons with HIV: real-life data from the ICONA Foundation cohortAlessandra Vergori, Antonella Castagna, Alessandro Cozzi-Lepri et al.|Journal of Antimicrobial Chemotherapy|2025Cited by 2
Durability of lenacapavir in viremic heavily treatment-experienced people with HIV: real-world data from the PRESTIGIO RegistryTommaso Clemente, Golnaz Torkjazi, Nicolò Capra et al.|Journal of Antimicrobial Chemotherapy|2025Cited by 0